Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Horm Metab Res ; 37(2): 89-93, 2005 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-15778925

RESUMO

OBJECTIVE: There is a high incidence of anemia in patients with advanced prostate cancer (PC) under androgen deprivation. Pathophysiology of this anemia remains unclear. Erythropoietin (EPO) is the main growth factor inducing erythropoesis in response to hypoxia. In this study, function of the EPO-system following androgen deprivation was tested in standardized animal model. METHODS: Animals were pretreated by either orchiectomy, injection of cyproteroneacetate or flutamide. After hypoxic stimulation, EPO mRNA expression and EPO serum levels were studied. RESULTS: In all animals, EPO mRNA expression and EPO serum levels were increased following hypoxic stimulation. Compared to the control group, this increase was even more pronounced after androgen deprivation. None of the different forms of androgen deprivation had a negative stimulating effect on EPO expression. CONCLUSION: Unexpectedly, androgen deprivation did not suppress EPO mRNA expression and EPO serum concentrations. Instead, stimulation of the EPO system was even more pronounced after androgen deprivation. A deficient EPO system does not appear to contribute to the clinically observed anemia in patients treated by androgen deprivation.


Assuntos
Antagonistas de Androgênios/administração & dosagem , Androgênios/deficiência , Anemia/fisiopatologia , Acetato de Ciproterona/administração & dosagem , Eritropoetina/biossíntese , Flutamida/administração & dosagem , Anemia/etiologia , Animais , Hematopoese/efeitos dos fármacos , Humanos , Masculino , Orquiectomia , Neoplasias da Próstata/complicações , Neoplasias da Próstata/fisiopatologia , Ratos , Ratos Wistar
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa